Core Insights - Polaryx Therapeutics, Inc. is actively participating in events to support the Krabbe disease community, demonstrating its commitment to advancing research and engaging with stakeholders [1][5] Event Participation - The company will attend the 2026 Krabbe Translational Research Network (KTRN) meeting from March 18-20, 2026, in Minneapolis, Minnesota, with key executives present [2] - The KTRN meeting aims to accelerate Krabbe research through focused, data-driven sessions that integrate insights across various aspects of the disease [3][4] - Polaryx will also participate in the 2026 Putt-Putt to CureKrabbe event on March 20, 2026, hosted by KrabbeConnect, to raise awareness and strengthen community engagement [5] Clinical Development - Polaryx is advancing the SOTERIA trial, a Phase 2, open-label, single-arm study to evaluate the safety, tolerability, and clinical activity of its lead candidate, PLX-200, across four rare lysosomal storage disorders (LSDs) [6][8] - The SOTERIA trial is designed to be flexible and resource-efficient, aiming to gather important data for PLX-200's future clinical development [8] - The trial is set to initiate in the first half of 2026, with sites in the United States, Europe, and Asia, following a safe to proceed letter from the FDA received in October 2025 [8][9] Scientific Insights - Recent findings on PLX-200 as a potential therapeutic approach for Krabbe disease have received positive feedback from the Krabbe community, emphasizing the importance of community engagement in clinical development [7] - Krabbe disease is caused by mutations in the GALC gene, leading to severe neurological decline due to the accumulation of toxic metabolites [7] Company Overview - Polaryx Therapeutics focuses on developing small molecule and gene therapy treatments for rare orphan lysosomal storage disorders, aiming to address significant unmet medical needs [10] - The company was founded in 2014 and seeks to deliver effective treatments that target the underlying pathophysiology of these diseases [10]